Literature DB >> 3154320

A multicenter study of a new inotropic agent, piperanometozine (OPC-8212) in congestive heart failure: clinical improvement during short-term treatment.

M Inoue1, M Hori, H Yasuda, T Takishima, T Sugimoto, S Sasayama, T Sakurai, H Nonogi, K Kodama, R Kusukawa.   

Abstract

Piperanometozine (OPC-8212) is a new, orally effective inotropic agent. To evaluate the efficacy of this agent on systemic hemodynamics and clinical symptoms in patients with congestive heart failure, a multicenter study was performed. Thirty four patients with New York Heart Association (NYHA) functional classes II to IV and initially treated with digitalis were enrolled from ten centers. After a washout period of one or two weeks (placebo period), digitalis was replaced by piperanometozine (30 or 60 mg/day) for four weeks, while other drugs were continued. Clinical symptoms, routine physical findings, electrocardiogram, chest roentgenogram, echocardiogram, exercise tolerance time, and routine laboratory data were obtained in 34 patients. Four patients were withdrawn from the study before completion. After the withdrawal of digitalis, heart rate was increased and ejection fraction was decreased. Exercise tolerance time was increased while other parameters were unchanged. At the end of the treatment period with piperanometozine, ejection fraction significantly (p less than 0.05) increased with a decrease in LV end-systolic volume (p less than 0.05), whereas heart rate and blood pressure remained unchanged. Systolic blood pressure/LV end-systolic volume (P/V index) tended to decrease after the withdrawal of digitalis and increase during piperanometozine therapy. Exercise tolerance time was further increased (p less than 0.01) and NYHA functional class was improved in 11 patients, whereas it worsened in only one patient. No major adverse effects were observed. These results indicate that a short-term therapy of oral piperanometozine restored the depressed cardiac performance of the heart and improved clinical symptoms in patients with congestive heart failure. Thus, this promising agent deserves further clinical study in long-term trials.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3154320     DOI: 10.1007/bf02125470

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  19 in total

1.  Left ventricular function in coronary artery disease. Evaluation of slope of end-systolic pressure-volume line (Emax) and ratio of peak systolic pressure to end-systolic volume (P/Ves).

Authors:  S El-Tobgi; F M Fouad; J R Kramer; G Rincon; W C Sheldon; R C Tarazi
Journal:  J Am Coll Cardiol       Date:  1984-03       Impact factor: 24.094

2.  M mode echocardiographic assessment of left ventricular function.

Authors:  R L Popp
Journal:  Am J Cardiol       Date:  1982-04-01       Impact factor: 2.778

3.  Effects of OPC-8212, a new positive inotropic agent, and dobutamine on left ventricular global and ischemic regional functions and coronary hemodynamics under coronary artery stenosis.

Authors:  Y Maruyama; O Nishioka; J Watanabe; M Keitoku; S Satoh; S Isoyama; K Ashikawa; E Ino-Oka; T Takishima
Journal:  J Cardiovasc Pharmacol       Date:  1986 Jan-Feb       Impact factor: 3.105

4.  Acute hemodynamic effects of a new positive inotropic agent, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), in conscious and anesthetized dogs.

Authors:  S Miyazaki; S Sasayama; Y Nakamura; Y Kihara; T Susawa; C Kawai
Journal:  J Cardiovasc Pharmacol       Date:  1986 Jan-Feb       Impact factor: 3.105

5.  Effects of in vivo beta-adrenoceptor down-regulation on cardiac responses to prenalterol and pirbuterol.

Authors:  T P Kenakin; R M Ferris
Journal:  J Cardiovasc Pharmacol       Date:  1983 Jan-Feb       Impact factor: 3.105

6.  Beneficial effect of OPC-8212 (3,4-dihydro-6-(4-(3,4-dimethoxy benzoyl)-1-piperazinyl)-2(1H)-quinolinone on myocardial oxygen consumption in dogs with ischemic heart failure.

Authors:  M Hori; M Inoue; J Tamai; Y Koretsune; M Kitakaze; K Iwai; K Iwakura; T Kamada
Journal:  Jpn Circ J       Date:  1986-07

7.  In vitro and in vivo studies of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), a novel positive inotropic drug, in various animals.

Authors:  S Yamashita; T Hosokawa; M Kojima; T Mori; Y Yabuuchi
Journal:  Arzneimittelforschung       Date:  1984

8.  Positive inotropic effect of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1 -piperazinyl]-2(1H)-quinolinone (OPC-8212) and mechanism of action in guinea pig ventricular myocardium.

Authors:  K Takeya; M Yajima; S Kobayashi-Ando; H Ando
Journal:  Arzneimittelforschung       Date:  1984

9.  Cardiotonic activity of a new inotropic agent, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), in the dog with and without beta-blocker and Ca++-antagonist pretreatment.

Authors:  M Hori; M Inoue; J Tamai; Y Koretsune; M Kitakaze; K Iwai; H Ito; A Kitabatake; T Kamada
Journal:  Jpn Circ J       Date:  1986-01

10.  Acute hemodynamic effects of a new inotropic agent, OPC-8212, on severe congestive heart failure.

Authors:  S Sasayama; M Inoue; H Asanoi; K Kodama; M Hori; T Sakurai; C Kawai
Journal:  Heart Vessels       Date:  1986       Impact factor: 2.037

View more
  2 in total

1.  Effect of OPC-8490 on the membrane potentials and membrane currents of single guinea-pig myocytes.

Authors:  Y Momose; S Sasayama
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

2.  A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. OPC-8212 Multicenter Research Group.

Authors: 
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.